Fair Accountability and Innovative Research Drug Pricing Act of 2021
Latest action · Mar 23, 2021 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 23, 2021
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Fair Accountability and Innovative Research Drug Pricing Act of 2021
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Cosponsors 5
Members who signed on, in the order they did. Signatures ran from Mar 23, 2021 to Jun 9, 2021, with 3 there on the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-AK | Lisa Murkowski | Original | Mar 23, 2021 |
| R-IN | Mike Braun | Original | Mar 23, 2021 |
| D-MN | Tina Smith | Original | Mar 23, 2021 |
| I-ME | Angus S. King Jr. | Jun 9, 2021 | |
| R-ND | John Hoeven | Jun 9, 2021 |
Actions 2
Everything that happened, newest first.
- Mar 23, 2021Introduced in Senate
- Mar 23, 2021Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 19 | Lower Costs, More Cures Act of 2021 | Related bill | Oct 19, 2021 |
| HR 9655 | Medicare for America Act of 2019 | Related bill | Dec 21, 2022 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Civil actions and liability
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Inflation and prices
- Manufacturing
- Marketing and advertising
- Medical research
- Prescription drugs
- Research and development
Text 1
Each version as it was printed, newest first.
- Mar 23, 2021Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.